ALGN vs. TEVA: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALGN and TEVA, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
TEVA stands out with 18.96 billion USD in market value—about 1.52× ALGN’s market cap of 12.46 billion USD.
ALGN’s beta of 1.68 points to much larger expected swings compared to TEVA’s calmer 0.63, suggesting both higher upside and downside potential.
TEVA is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ALGN, which is purely domestic.
| Symbol | ALGN | TEVA |
|---|---|---|
| Company Name | Align Technology, Inc. | Teva Pharmaceutical Industries Limited |
| Country | US | IL |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Drug Manufacturers - Specialty & Generic |
| CEO | Mr. Joseph M. Hogan | Mr. Richard D. Francis |
| Price | 171.91 USD | 16.55 USD |
| Market Cap | 12.46 billion USD | 18.96 billion USD |
| Beta | 1.68 | 0.63 |
| Exchange | NASDAQ | NYSE |
| IPO Date | January 30, 2001 | February 16, 1982 |
| ADR | No | Yes |
Performance Comparison
This chart compares the performance of ALGN and TEVA over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALGN and TEVA based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- TEVA shows a negative P/E of -14.61, highlighting a year of losses, whereas ALGN at 30.88 trades on solid profitability.
- TEVA shows a negative forward PEG of -1.13, signaling expected earnings contraction, while ALGN at 2.92 maintains analysts’ projections for stable or improved profits.
| Symbol | ALGN | TEVA |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 30.88 | -14.61 |
| Forward PEG Ratio (TTM) | 2.92 | -1.13 |
| Price-to-Sales Ratio (P/S, TTM) | 3.13 | 1.14 |
| Price-to-Book Ratio (P/B, TTM) | 3.33 | 3.00 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 19.76 | 24.73 |
| EV-to-EBITDA (TTM) | 14.56 | 23.01 |
| EV-to-Sales (TTM) | 2.94 | 2.06 |
| EV-to-Free Cash Flow (TTM) | 18.56 | 44.66 |
Dividend Comparison
Neither ALGN nor TEVA currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALGN | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALGN and TEVA, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- TEVA posts a quick ratio of 0.74, indicating limited coverage of short-term debts from its most liquid assets—while ALGN at 1.08 enjoys stronger liquidity resilience.
- ALGN shows “--” for interest coverage (indicating minimal interest cost). TEVA, however, with a ratio of 0.44, is not generating enough operating earnings to cover its current interest payments.
| Symbol | ALGN | TEVA |
|---|---|---|
| Current Ratio (TTM) | 1.21 | 1.03 |
| Quick Ratio (TTM) | 1.08 | 0.74 |
| Debt-to-Equity Ratio (TTM) | 0.03 | 2.71 |
| Debt-to-Assets Ratio (TTM) | 0.02 | 0.44 |
| Interest Coverage Ratio (TTM) | -- | 0.44 |